Literature DB >> 20666965

Complete remission with intraperitoneal cisplatin followed by prolonged oral etoposide in a stage IIIc primary leiomyosarcoma of the fallopian tube patient.

Yoichi Kobayashi1, Akiko Tozawa, Yoshiaki Okuma, Kazushige Kiguchi, Bunpei Ishizuka.   

Abstract

Leiomyosarcoma (LMS) of the fallopian tube is exceedingly uncommon. So far as we investigated, only eighteen cases of LMS of the fallopian tube have been reported. Here we report a nineteenth case which was International Federation of Gynecology and Obstetrics stage IIIc LMS of the fallopian tube successfully treated with intraperitoneal cisplatin followed by prolonged oral etoposide. A 70-year-old female was introduced to our institute due to intrapelvic tumor and ascites. Because of elevated serum lactate dehydrogenase and CA125 as well as the findings of pelvic magnetic resonance imaging and computerized tomography, the patient was suspected to have ovarian cancer. In laparotomy, the large pelvic tumor was seemed to originate from the right fallopian tube. Pathologically, the patient was diagnosed as stage IIIc fallopian tube LMS. At the end of the operation, cisplatin was given intraperitoneally followed by prolonged oral etoposide. Although a lot of dissemination was noted throughout the peritoneal cavity, the patient is alive without any evidence of recurrence for more than 6 years since the initial operation. In this uncommon entity, a cisplatin- and etoposide-based regimen could be considered.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20666965     DOI: 10.1111/j.1447-0756.2010.01241.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  1 in total

Review 1.  Primary leiomyosarcoma of the fallopian tube: A case report and literature review.

Authors:  Di You; Qilin Wang; Wei Jiang; Lin Lin; Tianjin Yi; Lingjun Zhao; Maomao Li; Ping Wang
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.